Premium
Niacin (vitamin B3, nicotinic acid) Decreases VLDLA‐polipoprotein B Secretion and Reduces Hepatic and Blood Lipid Concentrations: Roles of Niacin Metabolism and Autophagy Degradation
Author(s) -
Guo Liang,
Tuyama Ana,
Butkinaree Chutikarn,
Chung Kellie,
O'Donnell Michael D.,
Montet Emilie,
Fisher Edward A.
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.361.4
Subject(s) - niacin , medicine , endocrinology , very low density lipoprotein , apolipoprotein b , chemistry , triglyceride , lipoprotein , cholesterol , biology
Niacin therapy, used either alone or in combination with another agent to reduced the risk of coronary heart disease, is effective in raising and lowering, respectively, HDL‐c and apoB/VLDL triglyceride (TG) levels in dyslipidemia. To further understand if part of the mechanism is by reducing the secretion of apoB‐containing lipoproteins through autophagy, we did a series of niacin studies in isolated primary hepatocytes or in intact mice. Metabolic labeling and pulse‐chase results showed niacin increased intracellular apoB degradation by 30%, and decreased apoB/VLDL TG secretions by 40%. These effects were lost in autophagy‐deficient cells. Mice fed with diet containing 3% niacin had 40% increases in plasma HDL‐c. Feeding high fat diet (HFD) with niacin lowered LDL‐c by 50%. Niacin was able to suppress postprandial plasma triglyceride by 30%. Niacin reduced hepatic triglyceride and cholesterol concentrations by 40% and 50%, respectively, in mice fed with HFD. These data suggest niacin decreases hepatic lipid concentrations, apoB/VLDL secretion, and modifies plasma cholesterol levels. Some of the effects required niacin metabolism and autophagy degradation. Supported by grants from the NIH (HL58541) and Merck & Co., Inc. Grant Funding Source : NIH (HL58541) and Merck & Co., Inc.